BC-2 (ATCC® CRL-2231)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Disease: lymphoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain EBV and KSHV (HHV-8) viral genomes

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease lymphoma
Age 31 years adult
Gender male
Ethnicity Caucasian
Applications
transfection host
Derivation
BC-2 is a lymphoma cell line originated in 1992 by Ethel Cesarman and Giorgio Inghirami in the laboratory of Daniel M. Knowles.
The cells were derived from a pleural cavity based lymphomatous effusion.
Clinical Data
male
Caucasian
31 years adult
Antigen Expression
CD45 +; EMA + (epithelial membrane antigen)
Genes Expressed
CD45 +; EMA + (epithelial membrane antigen)
Comments
BC-2 is a lymphoma cell line originated in 1992 by Ethel Cesarman and Giorgio Inghirami in the laboratory of Daniel M. Knowles.
The cells were derived from a pleural cavity based lymphomatous effusion.
The cells contain two viral genomes: Epstein-Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV, provisionally designed HHV-8).
KSHV is a recently identified and largely uncharacterized virus.
The BC-2 cell line allows in vitro culture of KSHV viral genomes.
It is also a practical source of KSHV DNA to be used as a positive control for screening tests.
Complete Growth Medium RPMI 1640 medium, 80%; fetal bovine serum, 20%
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 2 X 10 exp6 cells/ml.
Cryopreservation
Culture medium, 95%; DMSO, 5%
Population Doubling Time 48 to 72 hrs
Name of Depositor Cornell Res. Fndn., Inc.
U.S. Patent Number
References

Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568

Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109

Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. PubMed: 8221575

Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568

Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109

Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. PubMed: 8221575

Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999